These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16725229)
1. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Seabrook TJ; Thomas K; Jiang L; Bloom J; Spooner E; Maier M; Bitan G; Lemere CA Neurobiol Aging; 2007 Jun; 28(6):813-23. PubMed ID: 16725229 [TBL] [Abstract][Full Text] [Related]
2. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202 [TBL] [Abstract][Full Text] [Related]
3. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. Seabrook TJ; Jiang L; Thomas K; Lemere CA J Neuroinflammation; 2006 Jun; 3():14. PubMed ID: 16753065 [TBL] [Abstract][Full Text] [Related]
4. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644 [TBL] [Abstract][Full Text] [Related]
5. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Subramanian S; Divya Shree AN Neurosci Lett; 2008 May; 436(2):219-22. PubMed ID: 18394801 [TBL] [Abstract][Full Text] [Related]
6. Species-specific immune response to immunization with human versus rodent A beta peptide. Seabrook TJ; Bloom JK; Iglesias M; Spooner ET; Walsh DM; Lemere CA Neurobiol Aging; 2004 Oct; 25(9):1141-51. PubMed ID: 15312960 [TBL] [Abstract][Full Text] [Related]
8. Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice. Seabrook TJ; Iglesias M; Bloom JK; Spooner ET; Lemere CA Vaccine; 2004 Sep; 22(29-30):4075-83. PubMed ID: 15364459 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. Bach P; Tschäpe JA; Kopietz F; Braun G; Baade JK; Wiederhold KH; Staufenbiel M; Prinz M; Deller T; Kalinke U; Buchholz CJ; Müller UC J Immunol; 2009 Jun; 182(12):7613-24. PubMed ID: 19494285 [TBL] [Abstract][Full Text] [Related]
10. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Muhs A; Hickman DT; Pihlgren M; Chuard N; Giriens V; Meerschman C; van der Auwera I; van Leuven F; Sugawara M; Weingertner MC; Bechinger B; Greferath R; Kolonko N; Nagel-Steger L; Riesner D; Brady RO; Pfeifer A; Nicolau C Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9810-5. PubMed ID: 17517595 [TBL] [Abstract][Full Text] [Related]
11. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Kim HD; Kong FK; Cao Y; Lewis TL; Kim H; Tang DC; Fukuchi K Neurosci Lett; 2004 Nov; 370(2-3):218-23. PubMed ID: 15488326 [TBL] [Abstract][Full Text] [Related]
13. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Sabbagh MN; Walker DG; Reid RT; Stadnick T; Anand K; Lue LF Neurosci Lett; 2008 Dec; 448(2):217-20. PubMed ID: 18926877 [TBL] [Abstract][Full Text] [Related]
14. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Weiner HL; Lemere CA; Maron R; Spooner ET; Grenfell TJ; Mori C; Issazadeh S; Hancock WW; Selkoe DJ Ann Neurol; 2000 Oct; 48(4):567-79. PubMed ID: 11026440 [TBL] [Abstract][Full Text] [Related]
15. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052 [TBL] [Abstract][Full Text] [Related]
16. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Kim HD; Maxwell JA; Kong FK; Tang DC; Fukuchi K Biochem Biophys Res Commun; 2005 Oct; 336(1):84-92. PubMed ID: 16126169 [TBL] [Abstract][Full Text] [Related]
17. Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. Cao C; Lin X; Zhang C; Wahi MM; Wefes I; Arendash G; Potter H J Neuroimmunol; 2008 Aug; 200(1-2):1-10. PubMed ID: 18649951 [TBL] [Abstract][Full Text] [Related]
18. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine. Li SB; Wang HQ; Lin X; Xu J; Xie Y; Yuan QF; Yao ZB Chin Med J (Engl); 2005 Apr; 118(8):660-4. PubMed ID: 15899121 [TBL] [Abstract][Full Text] [Related]
19. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711 [TBL] [Abstract][Full Text] [Related]
20. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides. Rossi M; Piovesan P; Ghirardi O; Mastroianni D; Bombardi V; Battistini L; Cencioni MT; Capobianco D; Borsini F; Colombo M; Verdoliva A Mol Immunol; 2009 Aug; 46(13):2524-32. PubMed ID: 19535144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]